Boehringer Ingelheim Licenses ProBioGen's Novel GlymaxX Technology

12-Aug-2011 - Germany

Boehringer Ingelheim and ProBioGen AG announced that they have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology. Boehringer Ingelheim’s Contract Manufacturing Business will apply the technology to enhance ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of antibodies.

The GlymaxX® technology for production of afucosylated proteins is universally applicable, simple and potent. As a unique feature, differentiating it from other approaches, the GlymaxX® technology can also be applied to already existing antibody producer cell lines without altering their productivity. The technology can easily be integrated into Boehringer Ingelheim’s high expression CHO-based BI-HEX® system.

Both Parties agreed to jointly market the technology and to offer it to customers royalty free.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

Last viewed contents